NTT-COMMUNICATIONS
28.9.2020 08:02:09 CEST | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), announced today that beginning October 1 it will collaborate with the International Data Spaces Association (IDSA)1 in a demonstration test as the first phase of contributing to the development of a secure, global data-management platform2 that assures interoperability between data platforms built and managed in countries worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200927005006/en/
The test environment for sharing highly confidential data securely will include IDS Connectors3 , the core technology of GAIA-X4 , a federated data infrastructure for Europe, and NTT Com’s Things Cloud® IoT platform and Smart Data Platform (SDPF)5 , the later incorporating Data Trust®6 policies. The demonstration, in addition to assessing the practicality and operability of a new structure for appropriately controlling the access rights of each data based on related laws and contracts, will shed new light on the requirements, etc. of platforms designed for international data management. The results are expected to lead to the establishment of global data management platforms that smoothly link local data platforms in countries across the globe.
In the demonstration, a test environment will be built to test various cases of international data sharing, such as remote monitoring of machines overseas, etc., to verify the practicality and operability of data sharing. Initially, in collaboration with the NTT Software Innovation Center,7 IDS Connector and SDPF will be deployed in a test environment in Japan to test system interoperability and the management of specific data-usage rights. The test environment in Japan will then be connected to IDSA’s test environment in Germany and a separate test environment at the Swiss nonprofit Switzerland Innovation Park Biel/Bienne8 to test the system’s practicality and operability in controlling data access rights internationally via NTT Com’s networks.
Thereafter, NTT Com will proceed with further verification and testing by applying the current test’s findings in a test operation environment (test bed), aiming to verify the interoperability of various hardware and software using the IDS Connector. The new global data management platform will be jointly developed by Japanese and overseas companies and organizations. At the same time, NTT Com will determine concrete requirements for the platform together with various organizations and companies active in Japan and overseas, including the Robot Revolution & Industrial IoT Initiative.9 Going forward, NTT Com hopes to support the formulation of basic specifications through public-private-academic collaboration. Ultimately, NTT Com aims to contribute to the realization of a smart world by developing and providing a platform for broad sharing and usage of data in wide-ranging fields worldwide.
Technologies for IoT, artificial intelligence and data utilization are increasingly being applied in diverse fields, including manufacturing, logistics, transportation, medical care, energy, cities and government. To facilitate advanced, multipurposed data use, systems are needed to ensure the safe, reliable exchange of data among industries, businesses and countries. Simultaneously, the rights of data providers and users must be protected and observed by managing when, where, who, why and under what conditions specific data can be used. Currently, legal systems and technologies are being developed worldwide to create such data infrastructure. Eventually, data exchange in international business may require compliance with data-infrastructure specifications according to the laws and regulations of relevant countries.
1 |
The International Data Spaces Association (IDSA), originating in Europe, has defined a reference architecture and a formal standard to be used for creating and operating virtual data spaces. The International Data Spaces (IDS) Architecture is based on commonly accepted data governance models facilitating secure exchange and easy linkage of data within business ecosystems. IDSA counts over 120 member organizations from 21 countries. |
2 |
Global data-management platform is a function for mutually linking data platforms across borders so that each country can internationally distribute data safely, fairly and appropriately while protecting national assets and human rights. |
3 |
IDS Connector provided by IDSA is the core element of a data ecosystem designed to facilitate the secure exchange of data between trusted parties. Deployed in the GAIA-X infrastructure as well as in clouds, on edge computers or on devices, etc. that send and receive data, it provides settings for managing access to specific data based on laws and contracts. |
4 |
GAIA-X is an initiative announced by the German and French governments in October 2019 to build decentralized data infrastructure for data sharing and utilization protected by European data laws. |
5 |
Smart Data Platform (SDPF) is NTT Com’s next-generation platform that offers comprehensive, one-stop functions for corporate digital transformation (DX). |
6 |
DATA Trust® is a registered trademark of Nippon Telegraph and Telephone Corporation (NTT). |
7 |
The NTT Software Innovation Center is an NTT laboratory engaged in researching and developing IT infrastructure technologies, such as DX acceleration, software infrastructure, AI infrastructure and next-generation computers, that are becoming important infrastructure. |
8 |
Switzerland Innovation Park Biel/Bienne is a Swiss private nonprofit organization that carries out and supports primarily industry-oriented applied research and development. |
9 |
The Robot Revolution & Industrial IoT Initiative is a private organization established in 2015 at the initiative of the Japanese government to facilitate the use of industrial IoT, robots, etc. NTT Com has been active as the secretariat of the Global Data Management Platform Sub-Working group since October 2019. |
About NTT Communications
NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2
of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com
| Twitter@NTT Com
| Facebook@NTT Com
| LinkedIn@NTT Com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200927005006/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
